

# Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. Reply.

**The authors reply:** We appreciate the interest of Dr. Zhang and colleagues in our article (1, 2). The main difference between our study and that by Zhang et al. (3) is that we assessed all rare predicted loss-of-function variants (pLOFs) meeting the same criteria in the case and control groups, which is a well-established paradigm in the field (4). In contrast, Zhang et al. included specific variants that were experimentally confirmed only in cases, but not in controls, precluding a valid case-control comparison.

We matched patients as closely as possible to those in the previous study, and the inclusion of more-severe cases (WHO grades 7–10) should only strengthen the signal against population controls. The use of population controls is standard in such settings and has minimal impact on power, because only a small proportion of individuals exposed to SARS-CoV-2 develop severe disease (5). Additionally, for the pLOF model, we report adequate power even for an odds ratio of 5.5, which is considerably lower than the one reported by Zhang et al. We tested the same dominant model as Zhang et al., even though LOF variants in these genes have only been reported to cause disease under recessive inheritance (6).

We have serious concerns about ancestry as a confounding factor in the analysis by Zhang et al., in which the pLOF carriers were mostly European, but functionally validated missense variants were found in individuals of various nationalities from Asia, Europe, Latin America, and the Middle East. Because the rates of pLOFs vary considerably across populations, adjustment for only 3 principal components of ancestry in rare-variant association tests of multiethnic cohorts does not provide adequate control for population structure.

While we noted that age differences may contribute to the discrepancies between the 2 studies, Zhang et al. do not discuss the role of age in the interpretation of their results, stating, “Inborn errors of TLR3- and IRF7-dependent type I IFN immunity at eight loci were found in as many as 23 patients (3.5%) of various ages (17–77 years) and ancestries (various nationalities from Asia, Europe, Latin America, and the Middle East) and in patients of both sexes.” We also note that the patients with autoantibodies were not excluded from the primary analysis by Zhang et al.; this was done only in the post hoc analysis.

Most importantly, our negative findings are in full agreement with the recently published independent sequencing study of 586,157 individuals, including 20,952 with COVID-19 (4928 hospitalized and 1304 with severe disease requiring ventilation or resulting in death; ref. 7). There were no significant associations with any of the 13 candidate genes examined either individually or in aggregate, or when comparisons included all hospitalized cases or only the most severe cases. Indeed, none of the associations showed even marginal significance. Therefore, consistent with our study, these findings do not support substantial contributions of inborn errors in type I IFN immunity to COVID-19 severity.

These negative results underscore the importance of proper study design, selection of appropriate genetic models, adequate control for genetic ancestry, and adherence to unbiased methods for genetic discovery rather than focusing only on a candidate biological pathway.

**Gundula Povysil,<sup>1</sup> Guillaume Butler-Laporte,<sup>2,3</sup> Ali G. Gharavi,<sup>4,5</sup> J. Brent Richards,<sup>2,3,6,7</sup> David B. Goldstein,<sup>1,8</sup> and Krzysztof Kiryluk<sup>4,5</sup>**

<sup>1</sup>Institute for Genomic Medicine, Columbia University, New York, New York, USA. <sup>2</sup>Lady Davis Institute for Medical Research, Montreal, Quebec, Canada. <sup>3</sup>Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada. <sup>4</sup>Department of Medicine and <sup>5</sup>Institute for Genomic Medicine, Columbia University, New York, New York, USA. <sup>6</sup>Department of Human Genetics, McGill University, Montreal, Canada. <sup>7</sup>Department of Twin Research, King's College London, London, United Kingdom. <sup>8</sup>Department of Genetics and Development, Columbia University, New York, New York, USA.

1. Povysil G, et al. Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. *J Clin Invest.* 2021;131(14):e147834.
2. Zhang Q, et al. Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. *J Clin Invest.* 2021;131(15):e152474.
3. Zhang Q, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science.* 2020;370(6515):eabd4570.
4. Povysil G, et al. Rare-variant collapsing analyses for complex traits: guidelines and applications. *Nat Rev Genet.* 2019;20(12):747–759.
5. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19 [published online July 8, 2021]. *Nature.* <https://doi.org/10.1038/s41586-021-03767-x>.
6. Cotsapas C, et al. Do monogenic inborn errors of immunity cause susceptibility to severe COVID-19? *J Clin Invest.* 2021;131(14):149459.
7. Kosmicki JA, et al. Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals [published online June 3, 2021]. *Am J Hum Genet.* <https://doi.org/10.1016/j.ajhg.2021.05.017>.

Address correspondence to: J. Brent Richards, 3755 Côte Sainte Catherine, Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2. Phone: 514.340.8222 ext. 24362; Email: [brent.richards@mcgill.ca](mailto:brent.richards@mcgill.ca). Or to: David B. Goldstein, 701 West 168th Street, New York, New York 10032, USA. Phone: 212.305.0923; Email: [dg2875@cumc.columbia.edu](mailto:dg2875@cumc.columbia.edu). Or to: Krzysztof Kiryluk, 1150 St. Nicholas Ave, New York, New York 10032, USA. Phone: 212.851.4926; Email: [kk473@columbia.edu](mailto:kk473@columbia.edu).

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: *J Clin Invest.* 2021;131(15):e152475. <https://doi.org/10.1172/JCI152475>.

See related letter: <https://doi.org/10.1172/JCI152474>.